What is Wave Life Sciences's latest dividend and current dividend yield?

What factors drove the changes in Wave Life Sciences's revenue and profit?

What does Wave Life Sciences do and what are its main business segments?

What is the market's earnings forecast for Wave Life Sciences next quarter?

What were the key takeaways from Wave Life Sciences's earnings call?

What were the key takeaways from Wave Life Sciences’s earnings call?

What is Wave Life Sciences's gross profit margin?

What guidance did Wave Life Sciences's management provide for the next earnings period?

- **Obesity Breakthrough**: WVE-007 Phase I data shows fat loss comparable to GLP-1s with muscle preservation. Phase IIa for higher BMI patients to begin H1 2026.
- **RNA Editing Leadership**: WVE-006 AATD program on track for mid-2026 FDA feedback. WVE-008 for PNPLA3 liver disease to enter clinic 2026.
- **Financial Strength**: $602M cash runway supports pipeline through 2028. GSK collaboration drives $2.8B+ potential milestones.
- **Strategic Differentiation**: Unique SpiNA design enables once/twice yearly dosing for WVE-007. RNA editing avoids DNA edits, targeting root cause of AATD.

**【CEO Summary Section】**
- **Obesity Program (WVE-007)**: Phase I data shows 4% total fat reduction, 9.2% visceral fat reduction, and muscle preservation at 240mg dose. Targeting once/twice yearly dosing. Phase IIa multi-dose study for higher BMI patients to begin H1 2026. Exploring add-on to GLP-1s and post-incretin maintenance therapy.
- **RNA Editing (WVE-006 for AATD)**: 400mg multi-dose data expected Q2 2026. Regulatory feedback on accelerated approval pathway anticipated mid-2026. 600mg data to follow. RNA editing avoids DNA edits and lipid nanoparticles, targeting mutant Z-AAT correction.
- **Pipeline Expansion**: WVE-008 for PNPLA3 liver disease (CTA 2026), DMD NDA submission 2026, and 4 GSK collaboration programs with $2.8B+ milestones.

**【CFO Financial Commentary】**
- **Q4 2025 Revenue**: $17.2M (vs. $83.7M prior year), driven by Takeda collaboration termination. Full year 2025 revenue $42.7M (vs. $108.3M prior year). GSK collaboration offsets部分收入下降.
- **R&D Expenses**: $52.8M (Q4) and $182.8M (FY2025), up 18% YoY, due to INHBE and RNA editing programs. G&A expenses $20.9M (Q4) and $75.3M (FY2025), up 27% YoY, driven by compensation.
- **Cash Position**: $602.1M as of Q4 2025, sufficient for operations into Q3 2028. Excludes potential GSK milestones.

**【Q&A Highlights】**
- **AATD Regulatory Pathway**: Aligned with competitor feedback, targeting M-AAT protein levels for accelerated approval. Mid-2026 FDA feedback expected.
- **Obesity Data Cadence**: 240mg 6-month and 400mg 3-month data to be shared Q2 2026. Phase IIa will include MRI-PDFF for liver fat assessment.
- **Competitive Differentiation**: WVE-007's SpiNA design enables 10x Ago2 loading vs. industry, driving durability. Preclinical fat loss comparable to GLP-1s without muscle loss.
- **Partnership Momentum**: GSK collaboration progressing with 4 programs in PRISM pipeline. Eligible for $2.8B+ milestones and royalties.


Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript

- **WVE-007 Milestones:** 85% activin E knockdown at 400mg, Q1 2026 data on 6-month durability and weight loss kinetics. Potential maintenance therapy post-GLP-1.
- **WVE-006 Success:** Restored acute phase response in AATD, with 64% M-AAT at 400mg. 600mg data expected Q1 2026.
- **Financial Strength:** $196M cash, runway to Q2 2027. Revenue growth driven by GSK collaboration.
- **Strategic Focus:** Obesity (INHBE) and AATD (RNA editing) as lead programs, with DMD and HD advancing for 2026 filings.
- **Key Regulatory Wins:** FDA alignment on MRI endpoints for HD, allele-selective approach for mutant Huntington reduction.

**【CEO Summary Section】**
- **WVE-007 (INHBE siRNA):** Dose-dependent activin E knockdown observed in Phase 1b (75mg: 56%, 240mg: 75%, 400mg: 85%), with durability up to 6 months. Targeting obesity as a maintenance therapy post-GLP-1 cessation. Q1 2026 data expected on 6-month follow-up (240mg) and 3-month (400mg). Preclinical data show fat loss without lean mass loss, aligning with human genetics reducing cardiometabolic risk.
- **WVE-006 (RNA Editing for AATD):** Achieved 64% M-AAT, 60% Z-AAT reduction, and restored acute phase response (20μM AAT post-dose). Q1 2026 data on 600mg multi-dose cohort. Potential for monthly dosing.
- **WVE-008 (PNPLA3 RNA Editing):** Clinical trial planned for 2026. Preclinical data show PNPLA3 restoration and lipid mobilization, addressing unmet need in liver disease.
- **DMD (WVE-N531):** Statistically significant 3.8s improvement in time to rise vs. natural history, with reduced fibrosis and inflammation. IND submission for monthly dosing in 2026.
- **HD (WVE-003):** Allele-selective reduction of mutant Huntington protein (46%), correlating with caudate atrophy slowing. Phase II/III study design aligned with FDA for accelerated approval.

**【CFO Financial Commentary】**
- **Q3 2025 Financials:** Revenue $7.6M (vs. -$7.7M prior year), R&D $45.9M (vs. $41.2M), G&A $18.1M (vs. $15M). Net loss $52.9M (vs. $61.8M). Cash $196.2M, extended runway to Q2 2027 with $72.1M ATM proceeds.
- **Partnerships:** Collaboration with GSK remains key, with no restrictions on INHBE program.

**【Q&A Highlights】**
- **Obesity Mechanism:** Fat loss driven by lipolysis without organ fat redistribution, supported by preclinical and genetic data. Early biomarker tracking includes metabolic health metrics.
- **HD Regulatory Path:** FDA alignment on MRI as surrogate endpoint, with caudate atrophy slowing correlating to clinical benefit (1% reduction delay disability by 7.5 years).
- **AATD Acute Response:** Single dose restored acute phase response, with potential for monthly dosing. Study protocol allows natural assessment of seasonal exacerbations.
- **DMD Capital Allocation:** Prudent advancement of exon 53 (WVE-N531) while evaluating collaborations for broader exon coverage.
- **INHBE Pricing Strategy:** GalNAc siRNA durability supports once/twice yearly dosing, addressing global obesity with cost-effective manufacturing.

Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript

- **Breakthrough Obesity Data**: WVE-007 cohort 2 expanded to 32 patients at 240mg, with 400mg dosing underway; Q4 2025 readout for 240mg weight loss potential.
- **RNA Editing Momentum**: WVE-006 multi-dose 200mg data Q3, targeting MZ phenotype conversion; 400mg single-dose data Q4.
- **Financial Resilience**: $208.5M cash runway into 2027; strategic focus on high-impact programs despite GSK collaboration timing headwinds.
- **Clinical Excellence**: 99% recruitment rate in INLIGHT cohort 2; 7/7 patients completing 200mg multi-dose in RestorAATion-2.

**【CEO Summary Section】**
- **AATD Program Progress**: WVE-006 (RNA editing) shows promising early data in RestorAATion-2 trial, with 8 patients completing 7 doses of 200mg, targeting MZ phenotype conversion. Multi-dose data expected Q3, 400mg single-dose data Q4.
- **Obesity Program Expansion**: WVE-007 (INHBE siRNA) cohort 2 expanded from 8 to 32 patients at 240mg due to favorable safety and Activin E reduction. Cohort 3 (400mg) dosing underway, with Q4 data readout for 240mg cohort.
- **DMD and HD Updates**: WVE-N531 (DMD) shows 3.8s improvement in time to rise vs natural history; NDA submission for accelerated approval in 2026. WVE-003 (HD) allele-selective approach targets mutant Huntington reduction, with Phase II/III trial design finalized.

**【CFO Financial Commentary】**
- **Revenue**: Q2 2025: $8.7M (YoY -56%) due to GSK collaboration timing.
- **Expenses**: R&D: $43.5M (YoY +7.7%), G&A: $18M (YoY +26%).
- **Cash**: $208.5M as of Q2, sufficient for operations into 2027.

**【Q&A Highlights】**
- **INHBE Dosing Strategy**: Expansion of cohort 2 driven by preclinical-DIO model alignment and safety; 400mg cohort initiated despite no weight loss data yet.
- **AATD Protein Targets**: Multi-dose 200mg expected to surpass single-dose M protein levels; MZ phenotype (≥60% M protein) sufficient for disease protection.
- **Regulatory Updates**: FDA alignment on N531 confirmatory trial design; no impact from recent SEDAR changes on DMD strategy.
- **Pipeline Efficiency**: Rapid recruitment in INLIGHT (32/32 in cohort 2) and RestorAATion-2 (7/7 doses completed) highlights operational execution strength.

Wave Life Sciences (WVE)-30 Jul 25-2025 Q2 Earnings call transcript

- **DMD Breakthrough**: WVE-N531 achieves 3.8s time to rise improvement at 48 weeks, with 88% >5% dystrophin. NDA submission for accelerated approval in 2026.
- **Obesity Innovation**: WVE-007 targets INHBE, showing fat-selective weight loss in preclinical studies. Human data expected H2 2025.
- **AATD Milestone**: WVE-006 achieves 6.9 µM M-AAT at 200 mg, with multi-dose data in Q3 2025 to inform dosing intervals.
- **Financial Strength**: $243M cash runway; R&D expenses up 21% YoY to fund pipeline expansion.
- **Key Differentiators**: RNA editing avoids DNA's bystander edits; allele-selective HD therapy preserves wild-type Huntington.
- **Cystic Fibrosis Expansion**: Preclinical data shows CFTR restoration in W1282X mutation, targeting untreated CF patients.

**【CEO Summary Section】**
- Wave Life Sciences reported significant clinical progress across its pipeline, including DMD (WVE-N531), obesity (WVE-007), AATD (WVE-006), and Huntington's disease (WVE-003). 
- WVE-N531 for DMD showed a 3.8-second improvement in time to rise vs. natural history at 48 weeks, with 88% of patients achieving >5% dystrophin expression. The company plans to submit an NDA for accelerated approval in 2026.
- WVE-007 for obesity targets INHBE, a novel mechanism orthogonal to GLP-1s, with preclinical data showing comparable weight loss without muscle loss. Initial human data expected in H2 2025.
- WVE-006 for AATD demonstrated RNA editing in humans, with 6.9 µM M-AAT achieved at 200 mg single dose. Multi-dose data expected in Q3 2025.
- WVE-003 for HD achieved 46% mutant Huntington reduction, correlating with slowed caudate atrophy. Phase II/III study expected to begin in H2 2025.

**【CFO Financial Commentary】**
- Q1 2025 revenue: $9.2M (down 26% YoY due to GSK collaboration timing).
- R&D expenses: $40.6M (up 21% YoY, driven by INHBE and RNA editing programs).
- G&A expenses: $18.4M (up 36% YoY, primarily share-based compensation).
- Cash balance: $243.1M, sufficient for operations into 2027.

**【Q&A Highlights】**
- **INHBE Program**: Data disclosure will follow predefined time points (1, 3, 6 months), with focus on fat loss vs. GLP-1s. Preclinical durability supports annual dosing.
- **Accelerated Approval Risks**: FDA confirmed dystrophin as a surrogate endpoint for DMD. Company plans to include 48-week functional data in NDA.
- **AATD Regulatory Path**: Phase II will define dosing frequency and M-AAT thresholds. Potential for bifurcated lung/hepatic endpoints.
- **Huntington's Competition**: WVE-003's allele-selective approach avoids wild-type Huntington reduction, differentiating from silencers like tominersen.
- **RNA Editing vs. DNA**: No bystander edits or indels; subcutaneous delivery avoids LNP-associated liver toxicity.
- **DMD Enrollment**: 11 boys in monthly dosing extension; expansion cohort size aligned with prior exon skippers.
- **Cystic Fibrosis Pipeline**: Preclinical data shows CFTR restoration in W1282X mutation, targeting ~10% of CF patients without treatment options.

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

- **Breakthrough RNA Editing in AATD:** WVE-006 achieved 10.8 µM total AAT and 6.9 µM M-AAT at 2 weeks, with multi-dose studies underway to extend durability. 
- **Obesity Innovation:** WVE-007 targets fat loss without muscle wasting; first clinical cohort fully enrolled, with data expected H2 2025. 
- **DMD Progress:** WVE-N531 shows 9% dystrophin at 24 weeks; 48-week data expected to inform regulatory path. 
- **Financial Strength:** $302M cash balance supports operations into 2027; R&D spend up 22% YoY to fuel pipeline expansion. 
- **HD Leadership:** WVE-003 demonstrates 46% mutant huntingtin reduction; Phase II/III trial targeting caudate atrophy as primary endpoint. 


**【CEO Summary Section】**
- Wave Life Sciences achieved significant clinical progress in 2024 across its RNA medicine pipeline, including positive data for AATD, DMD, and HD programs. 
- The company advanced WVE-007 (INHBE-silencing siRNA for obesity) into the clinic, with enrollment completed for the first cohort of the INLIGHT trial. 
- WVE-006 (RNA editing for AATD) demonstrated durable M-AAT protein production in patients, with 10.8 µM total AAT and 6.9 µM M-AAT at 2 weeks post-dose. 
- DMD program WVE-N531 showed 9% mean muscle dystrophin content at 24 weeks, with safety and tolerability data supporting monthly dosing. 
- Huntington's disease program WVE-003 achieved 46% mutant huntingtin reduction with preservation of wild-type protein, correlating with caudate atrophy slowing. 

**【CFO Financial Commentary】**
- Q4 2024 revenue was $83.7 million, driven by deferred revenue recognition from the Takeda collaboration. 
- Full-year 2024 R&D expenses were $159.7 million, up 22% YoY, reflecting investments in INHBE, AATD, and DMD programs. 
- G&A expenses were $59 million for the year, up 15% YoY, due to increased operational costs. 
- Net income for Q4 2024 was $29 million, compared to a net loss of $16.3 million in Q4 2023. 
- Cash balance ended the year at $302.1 million, up 51% YoY, supporting operations into 2027. 

**【Q&A Highlights】**
- **AATD (WVE-006):** Single-dose 200 mg achieved therapeutic M-AAT levels; multi-dose 200 mg and 400 mg cohorts underway to assess durability and extended dosing intervals. 
- **Obesity (WVE-007):** DEXA scans will measure fat loss vs. muscle preservation; target 50% INHBE silencing to replicate heterozygous INHBE loss-of-function benefits. 
- **DMD (WVE-N531):** FDA feedback expected by end-2025; 48-week data will include dystrophin levels, functional measures, and safety. 
- **HD (WVE-003):** Phase II/III trial targeting caudate atrophy as primary endpoint; IND submission planned for H2 2025. 
- **Pipeline Expansion:** RNA editing programs targeting PNPLA3, LDLR, and APOB in liver disease; preclinical data expected in 2025, with clinical trials starting in 2026. 


Actual										-1.38	-1.15	-0.86	-0.59	-0.86	-0.78	-0.12	-0.61	-0.62	-0.62	-0.42	-0.47	-0.27	-0.2	0.07	-0.15	-0.24	-0.25	-0.47	0.18	-0.29	-0.31	-0.32	-0.3
Forecast										-1.25	-1.0017	-0.6943	-0.5975	-0.5857	-0.6157	-0.6014	-0.5229	-0.5414	-0.5117	-0.4967	-0.41	-0.04	-0.3314	-0.1783	-0.2267	-0.186	-0.2074	-0.2828	-0.1788	-0.2595	-0.2773	-0.3042	-0.2738
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-10.40%	-14.80%	-23.87%	+1.26%	-46.83%	-26.69%	+80.05%	-16.66%	-14.52%	-21.16%	+15.44%	-14.63%	-575.00%	+39.65%	+139.26%	+33.83%	-29.03%	-20.54%	-66.20%	+200.67%	-11.75%	-11.79%	-5.19%	-9.57%

Actual	--	--	--	--	--	--	--	--	--	4.16M	3.03M	3.45M	9.44M	0	2.78M	36.42M	1.76M	1.75M	375.00K	285.00K	1.24M	12.93M	22.11M	49.21M	29.06M	12.54M	19.69M	-7.68M	83.75M	9.18M	8.70M	7.61M	17.24M
Forecast	--	--	--	--	--	--	--	--	--	5.90M	6.37M	12.63M	9.75M	10.08M	9.79M	10.36M	15.79M	3.86M	3.83M	8.20M	7.06M	32.33M	7.94M	23.43M	19.86M	25.00M	19.45M	16.61M	28.67M	11.92M	13.20M	12.63M	16.06M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-29.51%	-52.46%	-72.68%	-3.20%	-100.00%	-71.63%	+251.67%	-88.82%	-54.63%	-90.22%	-96.52%	-82.44%	-60.01%	+178.50%	+110.03%	+46.27%	-49.85%	+1.23%	-146.22%	+192.13%	-23.04%	-34.10%	-39.75%	+7.39%

WVE

WVE fundamentals

WVE Q4 2025 Earnings

Earnings Call

You can ask Aime

WVE

WVE fundamentals

WVE Q4 2025 Earnings

Earnings Call

WVE Earnings Call Summary for Q4/20258:30 AM on Feb 26, 2026

WVE Earnings Call Summary for Q3/20258:30 AM on Nov 10, 2025

WVE Earnings Call Summary for Q2/20258:30 AM on Jul 30, 2025

WVE Earnings Call Summary for Q1/20258:30 AM on May 8, 2025

WVE Earnings Call Summary for Q4/20248:30 AM on Mar 4, 2025

You can ask Aime